Worth reading
67In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-211
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationSecond quarter of the fiscal year ending December 202610 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥6,932 million+5.6%
Operating profit¥336 million-38.6%
Ordinary income¥398 million-24.2%
Net income¥260 million-37.0%
Selling, general and administrative expenses¥2,482 million
Full-year earnings forecast
Net Sales
¥13,960 million
Operating profit
¥760 million
Ordinary income
¥800 million
Net income for the current fiscal year
¥560 million
What the company explained in this material
New initiatives
- Establishment of CREATE MEDIC INDIA PVT. LTD., a sales company in India
- Launch of sales activities in the Indian market
- Launch of 2 new urology products
- Revision of the shareholder return policy and policy of targeting a 4% DOE
Key KPIsA metric the company considers important as a management benchmark.
- Overseas revenue ratio33.8 %
- Product lineup100 types or more
Segment results
In-house sales
Net Sales
¥3,850 million
Year on year against the same period last year+5.9%
Overseas sales
Net Sales
¥2,322 million
Year on year against the same period last year+1.2%
OEM Sales
Net Sales
¥759 million
Year on year against the same period last year+19.7%
Medium-term management plan targets
FY2027
Operating profit
¥13 million
Operating profit margin
8 %
Overseas revenue
¥57 million
Fiscal 2034
Operating profit
¥30 million
Operating profit margin
15 %
Overseas revenue
¥100 million
Overseas revenue ratio
50 %
Financial targets
Operating profit margin
2025 actual7.4 %
2027 target8 %
ROE
2025 actual4.4 %
2027 target7 %
PBR
2025 actual0.53 times
2027 target0.7 times
Number of employees
1,010 People
As ofEnd of December 2025
Capital expenditures
¥118 million
Annual Dividend
¥47
Interim20
End of period27
Payout ratio
50Acquisition of treasury shares
¥428 million
DetailsImplementation of Share Repurchases
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending December 2026 |
| Net Sales | ¥6,932 million (YoY +5.6%) |
| Operating profit | ¥336 million (YoY -38.6%) |
| Ordinary income | ¥398 million (YoY -24.2%) |
| Net income | ¥260 million (YoY -37.0%) |
| Selling, general and administrative expenses | ¥2,482 million |
| Full-year earnings forecast | Net Sales ¥13,960 million / Operating profit ¥760 million / Ordinary income ¥800 million / Net income for the current fiscal year ¥560 million |
| Segment results | In-house sales Net Sales ¥3,850 million / Year on year against the same period last year 5.9 % / Overseas sales Net Sales ¥2,322 million / Year on year against the same period last year 1.2 % / OEM Sales Net Sales ¥759 million / Year on year against the same period last year 19.7 % |
| Key KPIs | Indicator name Overseas revenue ratio / Value 33.8 % / Year on year against the same period last year Not disclosed, Indicator name Product lineup / Value 100 types or more / Year on year against the same period last year Not disclosed |
| Number of employees | 1,010 People |
| Medium-term management plan targets | FY2027 Operating profit ¥13 million / Operating profit margin 8 % / Overseas revenue ¥57 million / Fiscal 2034 Operating profit ¥30 million / Operating profit margin 15 % / Overseas revenue ¥100 million / Overseas revenue ratio 50 % |
| Financial targets | Operating profit margin 2025 actual 7.4 % / 2027 target 8 % / ROE 2025 actual 4.4 % / 2027 target 7 % / PBR 2025 actual 0.53 times / 2027 target 0.7 times |
| Annual Dividend | ¥47 |
| Payout ratio | 50 |
| Acquisition of treasury shares | ¥428 million |
| Capital expenditures | ¥118 million |
| New initiatives | Establishment of CREATE MEDIC INDIA PVT. LTD., a sales company in India, Launch of sales activities in the Indian market, Launch of 2 new urology products, Revision of the shareholder return policy and policy of targeting a 4% DOE |
Items this document does not state (13)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Direct sales were strong, driven by new urology products, while export sales also increased on higher sales of urology products to Europe. Gastroenterology products declined temporarily due to the impact of compliance with the European MDR. The cost of sales ratio rose as the yen weakened and due to the impact of concentrated purchasing in China, among other factors. Selling, general and administrative expenses increased due to costs related to the overseas strategy and inventory storage fees, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.